Volume 4, Issue 2 (2024)

Mechanistic language in molecular pharmacognosy often compresses several distinct evidentiary questions into a single claim: whether the phytochemical entity is correctly identified, whether a molecular target is merely predicted or physically engaged, whether perturbation of that target changes a relevant pathway, and whether the pathway contributes to the observed phenotype. This perspective examines why those questions should remain analytically separate and proposes a graded evidence ladder

Selecting a plant in-vitro production platform is often treated as a practical comparison among biomass growth, metabolite titre, transformability, and scale. That framing is incomplete when specialized-metabolite biosynthesis depends on differentiated cell identity, intercellular pathway partitioning, tissue-specific transport, or developmentally regulated competence. This original comparative decision article evaluates callus, suspension cells, hairy roots, and regenerated plants as biological

Microbial biotransformation offers access to selective oxidation, glycosylation, halogenation, methylation, amination, and other modifications of structurally complex plant natural products, yet catalytic possibility alone provides a poor basis for choosing useful transformations. A candidate reaction may be chemically plausible but fail because the relevant enzyme does not accept the scaffold, generates an unsuitable regioisomer or stereoisomer, performs differently in a microbial host, produce

Metabolomics can resolve striking chemical differences among medicinal-plant samples, but multivariate separation does not by itself identify the biological meaning of those differences. Similar clustering patterns may arise from inherited variation, population structure, geography, developmental stage, harvest timing, tissue composition, post-harvest processing, or analytical batch effects. This article develops an original evaluation framework for deciding when metabolomic differentiation can

Natural-product structures are commonly communicated as finished molecular identities, yet the analytical evidence underlying a drawing is heterogeneous in what it can establish. High-resolution mass spectrometry constrains elemental composition and fragmentation-compatible substructures; NMR defines connectivity and, with suitable restraints or calculations, stereochemical relationships; chiroptical methods can support absolute configuration; and biosynthetic reasoning can test chemical coheren

Natural products can advance discovery while remaining dependent on biological resources and production routes that are fragile, variable, or incompletely developed. Resupply is therefore not only a downstream manufacturing problem; it can influence whether a chemically or pharmacologically attractive candidate remains developable. This article develops an original translational resource-risk model that brings supply considerations forward to lead selection without treating ecological vulnerabil

Conventional extraction-based phytochemical analysis can identify many plant constituents but removes the anatomical context needed to determine where specialized metabolites accumulate, co-occur, or change within medicinal and bioactive plants. Mass-spectrometry imaging (MSI) addresses this spatial gap, although ion images differ substantially in chemical-identification confidence, quantitative meaning, and biological interpretability. This scoping review mapped peer-reviewed Q1 literature publ

Natural-product dereplication was established to reduce repeated isolation of known chemistry, but its practical meaning has broadened as mass spectrometry, molecular networking, public repositories, structure-prediction tools, and specialized databases have become integrated into discovery workflows. This review examines how the intellectual and technological organization of dereplication changed and whether the principal constraint shifted from detecting known compounds toward interpreting and